UK auditors slam diabetes care access failures and cost
This article was originally published in Clinica
England's failure to conduct a set of basic, annual checks on diabetes patients is causing a high number of preventable deaths and costing the health system three times what the government estimates, according to the UK’s public spending watchdog, the National Audit Office (NAO).
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.